A Phase 2 interventional study of Durvalumab and Placebo for Olaparib in Non-small Cell Lung Cancer NSCLC, sponsored by AstraZeneca. Active, not recruiting at 68 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 5 under way, 1 of them phase 3. olaparib · Carcinoma, Non-Small-Cell Lung.
Among the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 6th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
Fondazione Ricerca Traslazionale · Sites in Italy
Ages 18+
University of Leeds · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 1
First in 2011; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 186 across the 11 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 38th largest by enrollment of the 137 interventional ones that give a count, is one of 20 that started in 2018, is one of 38 in phase 2, reaches primary completion later than 4 of the 77 other live ones, and was the 112th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
1 of the studies testing olaparib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
Adult patients with a histologically or cytologically documented advanced NSCLC not amenable to curative surgery or radiation with tumors that lack activation EGFR mutations and ALK fusions are eligible for enrollment. During the initial therapy phase, patients will receive treatment with Durvalumab along with the Investigator's choice of platinum-based doublet therapy for squamous NSCLC (nab-paclitaxel plus carboplatin or gemcitabine plus carboplatin/cisplatin) and non-squamous NSCLC (nab-paclitaxel plus carboplatin or pemetrexed plus carboplatin/cisplatin) for 4 cycles. Patients who have completed 4 cycles and not progressed throughout the initial therapy phase will be randomized in a 1:1 ratio into the maintenance phase of the study to receive either Durvalumab plus placebo or Durvalumab plus Olaparib maintenance therapy. Patients will receive maintenance treatment until specific discontinuation criteria are met, including clinical disease progression (as assessed by the Investigator) or RECIST 1.1-defined radiological Progressive Disease (PD), unacceptable toxicity, and withdrawal of consent. Tumor evaluation scans will be performed until objective disease progression as efficacy assessments. All patients will be followed for survival until the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation.
Patients must have tumors that lack activating EGFR mutations and ALK fusions.
Key Inclusion criteria for randomization to maintenance treatment:
Exclusion criteria
Exclusion criteria to be randomized to maintenance treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Durvalumab/Olaparib Combination Therapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)
Drug: Durvalumab · Drug: Olaparib · Drug: Nab-paclitaxel+carboplatin · Drug: Gemcitabine+carboplatin · Drug: Pemetrexed+carboplatin · Drug: Gemcitabine+cisplatin · Drug: Pemetrexed+cisplatin
Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
Drug: Durvalumab · Drug: Placebo for Olaparib · Drug: Nab-paclitaxel+carboplatin · Drug: Gemcitabine+carboplatin · Drug: Pemetrexed+carboplatin · Drug: Gemcitabine+cisplatin · Drug: Pemetrexed+cisplatin
Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
Also known as: MEDI4736 (Durvalumab)
Matching tablet
Also known as: Placebo
150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
Also known as: AZD2281 (Olaparib)
Drug pages: Albumin-Bound Paclitaxel · Carboplatin
Standard of Care chemotherapy (squamous and non-squamous patients)
Drug pages: Gemcitabine · Carboplatin
Standard of Care chemotherapy (squamous patients only)
Drug pages: Pemetrexed · Carboplatin
Standard of Care chemotherapy (non-squamous patients only)
Drug pages: Gemcitabine · Cisplatin
Standard of Care chemotherapy (squamous patients only)
Drug pages: Pemetrexed · Cisplatin
Standard of Care chemotherapy (non-squamous patients only)
Progression-free Survival
Progression-free survival (PFS) based on investigator assessments according to Response Evaluation Criteria in Solid Tumours version 1.1. PFS is defined as time from date of randomization until the date of objective radiological disease progression using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).
Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Overall Survival
Overall survival (OS) across the maintenance phase. OS is defined as time from date of randomization until the date of death by any cause
Time frame: From randomization until the date of death due to any cause, up to 18 months.
Objective Response Rate
Objective response rate (ORR) defined as number of participants with complete response (CR) or partial response (PR) after randomization
Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Duration of Response
Duration of response (DoR) defined as time from the date of first documented response following randomization until the first date of documented progression or death in the absence of disease progression. Percentage of participants remaining in response at 3, 6, 9 and 12 months estimated using the Kaplan-Meier method.
Time frame: From date of first documented response until objective radiological disease progression or death, up to 18 months.
Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population
Progression-free survival in homologous recombination repair related gene mutation (HRRm) population defined as time from date of randomization until the date of objective radiological disease progression in HRRm population using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).
Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Concentration of Durvalumab
Concentration (pharmacokinetics) of durvalumab
Time frame: Assessed from start of initial therapy up to 2 years.
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
Disease-related symptoms assessed by change from baseline (for maintenance phase) in EORTC QLQ-LC13. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-LC13 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales in the EORTC QLQ-LC13. Higher scores on symptom scales represent greater symptom severity.
Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
Disease-related symptoms assessed by time to deterioration (for maintenance phase) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13. Symptom deterioration is defined as an increase in the score from baseline of less than or equal to 10) that is confirmed at a subsequent assessment, or death (by any cause) in the absence of a clinically meaningful symptom deterioration. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.
Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
Disease-related symptoms and health-related quality of life (HRQoL) assessed by change from baseline (for maintenance phase) in EORTC QLQ-C30. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-C30 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales, each of the function scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and function scales indicate better health status/function. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Includes all assessments occurring within the first 12 months of randomization or until disease progression, up to 18 months.
Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
Disease-related symptoms and health-related quality of life (HRQoL) assessed by time to deterioration (for maintenance phase) in EORTC QLQ-C30. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.
Time frame: From randomization until date of first symptom deterioration that is confirmed, up to 18 months.
Presence of Anti-drug Antibodies (ADAs) for Durvalumab
Presence of anti-drug antibodies (ADAs) for durvalumab, as assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 and 6 months after last dose of durvalumab
Time frame: Assessed from start of initial therapy up to 2 years.
Number of Participants With Treatment-Related Adverse Events
Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
| Milestone | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Started | 0 | 401 |
| Completed | 0 | 269 |
| Not completed | 0 | 132 |
| Withdrew: Other reason provided | 0 | 15 |
| Withdrew: Condition under investigation worsened | 0 | 67 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Adverse event | 0 | 34 |
| Withdrew: Withdrawal by subject | 0 | 14 |
| Milestone | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Started | 134 | 135 |
| Participants who received durvalumab | 134 | 134 |
| Participants who received olaparib/placebo | 128 | 128 |
| Participants who terminated the study | 57 | 57 |
| Completed | 77 | 78 |
| Not completed | 57 | 57 |
| Withdrew: Withdrawal by subject | 13 | 12 |
| Withdrew: Death | 44 | 45 |
Progression-free survival (PFS) based on investigator assessments according to Response Evaluation Criteria in Solid Tumours version 1.1. PFS is defined as time from date of randomization until the date of objective radiological disease progression using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).
| Participants | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| RECIST progression: Target Lesions | 40 | 63 |
| RECIST progression: Non Target Lesions | 28 | 30 |
| RECIST progression: New Lesions | 44 | 39 |
| Death in the absence of progression | 8 | 9 |
| Censored subjects: Censored RECIST progression | 0 | 0 |
| Censored subjects: Censored death | 1 | 0 |
| Censored subjects: Progression-free at time of analysis | 44 | 34 |
| Censored subjects: Progression-free prior to lost to follow-up | 0 | 0 |
| Censored subjects: Progression-free prior to withdrawal of consent | 3 | 2 |
| Censored subjects: Progression-free prior to discontinuation due to other reason | 0 | 0 |
| Censored subjects: No post-baseline evaluable tumor assessment | 2 | 2 |
Overall survival (OS) across the maintenance phase. OS is defined as time from date of randomization until the date of death by any cause
| Participants | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Death | 44 | 45 |
| Censored participants (still in survival at follow up or terminated study prior to death) | 90 | 90 |
Objective response rate (ORR) defined as number of participants with complete response (CR) or partial response (PR) after randomization
| Participants | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Response | 22 | 18 |
| No Response | 107 | 113 |
Duration of response (DoR) defined as time from the date of first documented response following randomization until the first date of documented progression or death in the absence of disease progression. Percentage of participants remaining in response at 3, 6, 9 and 12 months estimated using the Kaplan-Meier method.
| percent | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Percentage of participants remaining in response at 3 months | 90.5 | 85.1 |
| Percentage of participants remaining in response at 6 months | 79.1 | 65.7 |
| Percentage of participants remaining in response at 9 months | 69.2 | 65.7 |
| Percentage of participants remaining in response at 12 months | 69.2 | 65.7 |
Progression-free survival in homologous recombination repair related gene mutation (HRRm) population defined as time from date of randomization until the date of objective radiological disease progression in HRRm population using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).
| Participants | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| RECIST progression: Target Lesions | 1 | 5 |
| RECIST progression: Non Target Lesions | 2 | 2 |
| RECIST progression: New Lesions | 3 | 3 |
| Death in the absence of progression | 0 | 0 |
| Censored subjects: Censored RECIST progression | 0 | 0 |
| Censored subjects: Censored death | 0 | 0 |
| Censored subjects: Progression-free at time of analysis | 2 | 2 |
| Censored subjects: Progression-free prior to lost to follow-up | 0 | 0 |
| Censored subjects: Progression-free prior to withdrawal of consent | 0 | 0 |
| Censored subjects: Progression-free prior to discontinuation due to other reason | 0 | 0 |
| Censored subjects: No post-baseline evaluable tumor assessment | 0 | 0 |
Concentration (pharmacokinetics) of durvalumab
| μg/mL | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Cycle 01 Day 01 (Initial Therapy Phase) Post dose | 417.152 ± 62.694 | 453.724 ± 43.258 |
| Cycle 02 Day 01 (Initial Therapy Phase) Pre dose | 76.812 ± 84.586 | 76.959 ± 71.104 |
| Cycle 04 Day 01 (Initial Therapy Phase) Pre dose | 155.461 ± 58.251 | 154.947 ± 50.102 |
| Cycle 01 (Maintenance Phase) Post dose | 535.078 ± 40.119 | 524.306 ± 56.458 |
| Cycle 02 (Maintenance Phase) Pre dose | 159.157 ± 53.813 | 160.315 ± 54.409 |
| Cycle 05 (Maintenance Phase) Pre dose | 166.644 ± 54.948 | 147.848 ± 56.204 |
| Cycle 08 (Maintenance Phase) Pre dose | 198.932 ± 47.024 | 154.057 ± 54.911 |
| Cycle 11 (Maintenance Phase) Pre dose | 210.794 ± 42.117 | 186.092 ± 39.823 |
| Cycle 14 (Maintenance Phase) Pre dose | 276.612 ± 50.137 | 182.042 ± 39.341 |
| Cycle 17 (Maintenance Phase) Pre dose | 264.096 ± 55.519 | 217.137 ± 92.229 |
| Cycle 20 (Maintenance Phase) Pre dose | 528.046 | 112.276 |
| Month 03 (Maintenance Phase) Pre dose | 12.289 ± 450.125 | 12.769 ± 225.898 |
Disease-related symptoms assessed by change from baseline (for maintenance phase) in EORTC QLQ-LC13. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-LC13 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales in the EORTC QLQ-LC13. Higher scores on symptom scales represent greater symptom severity.
| change from baseline score | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| EORTC QLQ-LC13: Dyspnoea | -1.27 ± 1.373 | -0.76 ± 1.500 |
| EORTC QLQ-LC13: Coughing | -2.14 ± 1.980 | -3.09 ± 2.172 |
| EORTC QLQ-LC13: Pain in chest | 1.31 ± 1.410 | 3.57 ± 1.575 |
Disease-related symptoms assessed by time to deterioration (for maintenance phase) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13. Symptom deterioration is defined as an increase in the score from baseline of less than or equal to 10) that is confirmed at a subsequent assessment, or death (by any cause) in the absence of a clinically meaningful symptom deterioration. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.
| months | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| EORTC QLQ-LC13: Dyspnoea | 10.0 (5.6 to 12.2) | 9.7 (6.9 to 12.0) |
| EORTC QLQ-LC13: Coughing | 11.7 (9.3 to NA) | 10.6 (7.7 to 12.6) |
| EORTC QLQ-LC13: Haemoptysis | 15.0 (11.7 to NA) | 12.6 (10.9 to NA) |
| EORTC QLQ-LC13: Pain In Chest | 13.8 (10.8 to NA) | 11.5 (9.5 to NA) |
| EORTC QLQ-LC13: Pain In Arm Or Shoulder | 15.0 (10.2 to NA) | 9.7 (7.4 to 12.6) |
| EORTC QLQ-LC13: Pain In Other Parts | 10.3 (8.8 to 12.2) | 10.6 (8.6 to NA) |
Disease-related symptoms and health-related quality of life (HRQoL) assessed by change from baseline (for maintenance phase) in EORTC QLQ-C30. Average adjusted mean over first 11 cycles is presented. The EORTC QLQ-C30 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales, each of the function scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and function scales indicate better health status/function. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
| change from baseline score | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| EORTC QLQ-C30: Fatigue | 0.15 ± 1.327 | -1.49 ± 1.456 |
| EORTC QLQ-C30: Appetite loss | -0.13 ± 1.613 | -3.35 ± 1.779 |
Disease-related symptoms and health-related quality of life (HRQoL) assessed by time to deterioration (for maintenance phase) in EORTC QLQ-C30. NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.
| time to deterioration (months) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| EORTC QLQ-C30: Fatigue | 8.8 (5.6 to 10.8) | 10 (8.0 to 12.6) |
| EORTC QLQ-C30: Nausea And Vomiting | 12.2 (10.2 to 15.0) | 12.6 (9.7 to NA) |
| EORTC QLQ-C30: Pain | 10.2 (7.4 to 12.2) | 9.7 (6.6 to 12.6) |
| EORTC QLQ-C30: Dyspnoea | 12.2 (10.0 to NA) | 11.0 (8.8 to NA) |
| EORTC QLQ-C30: Insomnia | 13.8 (10.0 to NA) | 10.6 (8.6 to 12.6) |
| EORTC QLQ-C30: Appetite Loss | 11.7 (10.1 to NA) | 11.5 (10.0 to NA) |
| EORTC QLQ-C30: Constipation | 12.2 (10.0 to NA) | 12.0 (10.0 to NA) |
| EORTC QLQ-C30: Diarrhoea | 13.8 (10.2 to NA) | 11.5 (9.7 to NA) |
| Physical Functioning | 12.0 (9.3 to NA) | 12.0 (9.0 to NA) |
| Role Functioning | 10.0 (5.6 to 12.2) | 10.6 (8.8 to NA) |
| Emotional Functioning | 12.2 (9.3 to NA) | 11.0 (8.8 to 12.6) |
| Cognitive Functioning | 10.2 (6.9 to NA) | 10.6 (8.6 to 12.6) |
| Social Functioning | 9.3 (7.4 to 12.2) | 10.0 (7.7 to NA) |
| Global Health Status/Quality of Life | 10.2 (6.5 to 12.2) | 9.7 (7.4 to 12.0) |
Presence of anti-drug antibodies (ADAs) for durvalumab, as assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 and 6 months after last dose of durvalumab
| Participants | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| ADA prevalence (any ADA positive, baseline or post-baseline) | 11 | 9 |
| ADA incidence (treatment-induced or treatment-boosted) | 5 | 4 |
| ADA positive post-baseline and positive at baseline | 0 | 1 |
| ADA positive post-baseline and not detected at baseline (treatment-induced) | 5 | 4 |
| ADA not detected at post-baseline and positive at baseline | 6 | 4 |
| Treatment-boosted ADA | 0 | 0 |
| Persistent positive | 0 | 3 |
| Transient positive | 5 | 2 |
| Neutralizing anti-drug antibody positive at any visit | 1 | 1 |
Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)
| Participants | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|
| Number of Participants With Treatment-Related Adverse Events | 83 | 54 |
Collected over From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Therapy Phase | 89/401 (22.2%) | 104/401 (25.9%) | 368/401 (91.8%) |
| Durvalumab/Olaparib Combination Therapy | 44/134 (32.8%) | 25/134 (18.7%) | 116/134 (86.6%) |
| Durvalumab/Placebo Therapy | 45/135 (33.3%) | 19/134 (14.2%) | 104/134 (77.6%) |
| Event | Initial Therapy Phase | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|---|
| PneumoniaInfections and infestations | 16/401 | 3/134 | 2/134 |
| AnaemiaBlood and lymphatic system disorders | 13/401 | 5/134 | 0/134 |
| NeutropeniaBlood and lymphatic system disorders | 6/401 | 1/134 | 0/134 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/401 | 0/134 | 0/134 |
| Atrial fibrillationCardiac disorders | 0/401 | 2/134 | 0/134 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/401 | 1/134 | 2/134 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/401 | 0/134 | 2/134 |
| Disease progressionGeneral disorders | 1/401 | 0/134 | 2/134 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/401 | 0/134 | 1/134 |
| DehydrationMetabolism and nutrition disorders | 4/401 | 0/134 | 0/134 |
| Event | Initial Therapy Phase | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 188/401 | 35/134 | 11/134 |
| NauseaGastrointestinal disorders | 118/401 | 19/134 | 10/134 |
| NeutropeniaBlood and lymphatic system disorders | 92/401 | 0/134 | 0/134 |
| ConstipationGastrointestinal disorders | 70/401 | 0/134 | 0/134 |
| FatigueGeneral disorders | 68/401 | 15/134 | 9/134 |
| ThrombocytopeniaBlood and lymphatic system disorders | 60/401 | 0/134 | 0/134 |
| DiarrhoeaGastrointestinal disorders | 53/401 | 11/134 | 6/134 |
| LeukopeniaBlood and lymphatic system disorders | 49/401 | 0/134 | 0/134 |
| Decreased appetiteMetabolism and nutrition disorders | 1/401 | 16/134 | 9/134 |
| Neutrophil count decreasedInvestigations | 46/401 | 0/134 | 0/134 |
The full analysis set for the maintenance phase is presented
| Age, Continuous(Years) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Mean age (years) | 65.9 ± 9.59 | 63.0 ± 9.50 | 64.5 ± 9.64 |
| Age, Customized(participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Less than 50 years | 7 | 14 | 21 |
| Equal to or greater than 50 years to less than 65 years | 49 | 55 | 104 |
| Equal to or greater than 65 years to less than 75 years | 54 | 54 | 108 |
| Equal to or greater than 75 years | 24 | 12 | 36 |
| Sex: Female, Male(Participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Female | 36 | 38 | 74 |
| Male | 98 | 97 | 195 |
| Ethnicity (NIH/OMB)(Participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 132 | 132 | 264 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 37 | 45 | 82 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 96 | 89 | 185 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Smoking Status(Participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Current | 35 | 31 | 66 |
| Former | 74 | 72 | 146 |
| Never | 25 | 32 | 57 |
| Histology Type(participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Squamous Cell Carcinoma | 58 | 59 | 117 |
| Nonsquamous Cell Carcinoma | 76 | 76 | 152 |
| World Health Organization/Eastern Cooperative Oncology Group(participants) | Durvalumab/Olaparib Combination Therapy | Durvalumab/Placebo Therapy | Total |
|---|---|---|---|
| Normal Activity | 52 | 54 | 106 |
| Restricted Activity | 81 | 80 | 161 |
| In Bed Less Than or Equal to 50 percent of the Time | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2018 to primary completion in Jan 2021, 24 months.
Results were first posted in Dec 2022, 1 year 11 months after primary completion. A results delay was requested in Dec 2021.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 24 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib
Carcinoma, Non-Small-Cell Lung →